Abstract
Systematic searches for plasma proteins that are biological indicators, or biomarkers, for cancer are underway. The difficulties caused by the complexity of biological-fluid proteomes and tissue proteomes (which contribute proteins to plasma) and by the extensive heterogeneity among diseases, subjects and levels of sample procurement are gradually being overcome. This is being achieved through rigorous experimental design and in-depth quantitative studies. The expected outcome is the development of panels of biomarkers that will allow early detection of cancer and prediction of the probable response to therapy. Achieving these objectives requires high-quality specimens with well-matched controls, reagent resources, and an efficient process to confirm discoveries through independent validation studies.
Similar content being viewed by others
References
Ludwig, J. A. & Weinstein, J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nature Rev. Cancer 5, 845–856 (2005).
Cox, J. & Mann, M. Is proteomics the new genomics? Cell 130, 395–398 (2007). This is a review of current mass-spectrometry-based proteomic technologies. It explores the relationship between genomics and proteomics and the outlook for protein-expression analysis.
Faca, V. et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J. Proteome Res. 6, 3558–3565 (2007).
Wu, S. L. et al. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). Mol. Cell. Proteomics 5, 1610–1627 (2006).
Liu, T., Belov, M. E., Jaitly, N., Qian, W. J. & Smith, R. D. Accurate mass measurements in proteomics. Chem. Rev. 107, 3621–3653 (2007).
Liu, X. et al. Mapping the human plasma proteome by SCX–LC–IMS–MS. J. Am. Soc. Mass Spectrom. 18, 1249–1264 (2007).
Stahl-Zeng, J., Lange, V., Ossola, R., Aebersold, R. & Domon, B. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 6, 1809–1817 (2007).
Kingsmore, S. F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nature Rev. Drug Discov. 5, 310–320 (2006).
Chignard, N. et al. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: detection of generated fragments in patient sera. Gastroenterology 130, 2010–2022 (2006).
Hu, S., Loo, J. A. & Wong, D. T. Human body fluid proteome analysis. Proteomics 6, 6326–6353 (2006).
Kim, S. W. et al. Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air–liquid interface method. Cancer Res. 67, 6565–6573 (2007).
Kulasingam, V. & Diamandis, E. P. Proteomic analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics 6, 1997–2011 (2007).
States, D. J. et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nature Biotechnol. 24, 333–338 (2006). This paper describes the first large-scale collaborative study to characterize the human serum and plasma proteomes.
Zhang, H. et al. Mass spectrometric detection of tissue proteins in plasma. Mol. Cell. Proteomics 6, 64–71 (2007).
Ransohoff, D. F. Bias as a threat to the validity of cancer molecular-marker research. Nature Rev. Cancer 5, 142–149 (2005). This review outlines the experimental pitfalls of cancer biomarker research and suggests ways to avoid bias in clinical research.
Gao, W. et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5, 110, doi:10.1186/1471-2407-5-110 (2005).
Okano, T. et al. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin. Cancer Res. 13, 799–805 (2007).
Taguchi, F. et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl Cancer Inst. 99, 838–846 (2007).
Villanueva, J. et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5, 1840–1852 (2006).
Kirmiz, C. et al. A serum glycomics approach to breast cancer biomarkers. Mol. Cell. Proteomics 6, 43–55 (2007).
Kyselova, Z. et al. Alterations in the serum glycome due to metastatic prostate cancer. J. Proteome Res. 6, 1822–1832 (2007).
Barrabes, S. et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 17, 388–400 (2007).
Zhao, J., Qiu, W., Simeone, D. M. & Lubman, D. M. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J. Proteome Res. 6, 1126–1138 (2007).
Syka, J. E., Coon, J. J., Schroeder, M. J., Shabanowitz, J. & Hunt, D. F. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl Acad. Sci. USA 101, 9528–9533 (2004).
Chatterjee, M. et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 66, 1181–1190 (2006).
Wang, X. et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224–1135 (2005).
Hudson, M. E., Pozdnyakova, I., Haines, K., Mor, G. & Snyder, M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl Acad. Sci. USA 104, 17494–17499 (2007).
Philip, R. et al. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J. Proteome Res. 6, 2509–2517 (2007).
Brichory, F. M. et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl Acad. Sci. USA 98, 9824–9829 (2001).
Pereira-Faca, S. et al. Identification of 14-3-3θ as an antigen that induces a humoral response in lung cancer. Cancer Res. 67, 12000–12006 (2007).
Madoz-Gurpide, J., Kuick, R., Wang, H., Misek, D. E. & Hanash, S. M. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol. Cell. Proteomics 7, 268–281 (2008).
Yasui, Y. et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4, 449–463 (2003).
Tada, H., Higuchi, H., Wanatabe, T. M. & Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 67, 1138–1144 (2007).
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. & Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnol. 22, 969–976 (2004).
Shafer, M. W., Mangold, L., Partin, A. W. & Haab, B. B. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease. Prostate 67, 255–267 (2007).
Fredriksson, S. et al. Protein detection using proximity-dependent DNA ligation assays. Nature Biotechnol. 20, 473–477 (2002).
Kato, K., Ishimuro, T., Arima, Y., Hirata, I. & Iwata, H. High-throughput immunophenotyping by surface plasmon resonance imaging. Anal. Chem. 79, 8616–8923 (2007).
Burg, T. P. et al. Weighing of biomolecules, single cells and single nanoparticles in fluid. Nature 446, 1066–1069 (2007).
Kuhn, E. et al. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 4, 1175–1186 (2004).
Hoppe-Seyler, F. & Butz, K. Peptide aptamers: powerful new tools for molecular medicine. J. Mol. Med. 78, 426–430 (2000).
Cerchia, L., Hamm, J., Libri, D., Tavitian, B. & de Franciscis, V. Nucleic acid aptamers in cancer medicine. FEBS Lett. 528, 12–16 (2002).
Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966–971 (2007). This paper describes the highly concordant nature of mouse cancer models and the human cancer genome.
Lu, H., Knutson, K. L., Gad, E. & Disis, M. L. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res. 66, 9754–9761 (2006).
Chen, R. et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129, 1187–1197 (2006).
Chen, R. et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell. Proteomics 6, 1331–1342 (2007)
Chen, R. et al. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34, 70–79 (2007).
Lin, Y. et al. Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J. Proteome Res. 5, 2169–2176 (2006).
Yu, K. H., Rustgi, A. K. & Blair, I. A. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J. Proteome Res. 4, 1742–1751 (2005).
Wang, Y., Wu, S. L. & Hancock, W. S. Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap–Fourier transform mass spectrometry (LTQ/FTMS). Glycobiology 6, 514–523 (2006).
Acknowledgements
We thank B. L. Karger and S. L. Wu for assistance with Fig. 3.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Reprints and permissions information is available at http://npg.nature.com/reprints.
Correspondence should be addressed to S.M.H. (shanash@fhcrc.org).
Rights and permissions
About this article
Cite this article
Hanash, S., Pitteri, S. & Faca, V. Mining the plasma proteome for cancer biomarkers. Nature 452, 571–579 (2008). https://doi.org/10.1038/nature06916
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature06916
- Springer Nature Limited
This article is cited by
-
Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables
Clinical Proteomics (2023)
-
The application of Aptamer in biomarker discovery
Biomarker Research (2023)
-
Proteomic analysis identifies dysregulated proteins and associated molecular pathways in a cohort of gallbladder cancer patients of African ancestry
Clinical Proteomics (2023)
-
Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation
Nature Communications (2023)
-
Detection and analysis of chiral molecules as disease biomarkers
Nature Reviews Chemistry (2023)